scholarly journals Non-Exposure Endoscopic-Laparoscopic Cooperative Surgery for Stomach Tumors

2018 ◽  
Vol 51 (2) ◽  
pp. 113-114 ◽  
Author(s):  
Hyo-Jung Oh ◽  
Chan-Young Kim
Keyword(s):  
2015 ◽  
Vol 33 (28) ◽  
pp. 3130-3136 ◽  
Author(s):  
Se Hoon Park ◽  
Tae Sung Sohn ◽  
Jeeyun Lee ◽  
Do Hoon Lim ◽  
Min Eui Hong ◽  
...  

Purpose The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) in patients with D2-resected gastric cancer (GC). Patients and Methods Between November 2004 and April 2008, 458 patients with GC who received gastrectomy with D2 lymph node dissection were randomly assigned to either six cycles of adjuvant chemotherapy with capecitabine and cisplatin (XP) or to two cycles of XP followed by chemoradiotherapy and then two additional cycles of XP (XPRT). This final update contains the first publication of overall survival (OS), together with updated DFS and subset analyses. Results With 7 years of follow-up, DFS remained similar between treatment arms (hazard ratio [HR], 0.740; 95% CI, 0.520 to 1.050; P = .0922). OS also was similar (HR, 1.130; 95% CI, 0.775 to 1.647; P = .5272). The effect of the addition of radiotherapy on DFS and OS differed by Lauren classification (interaction P = .04 for DFS; interaction P = .03 for OS) and lymph node ratio (interaction P < .01 for DFS; interaction P < .01 for OS). Subgroup analyses also showed that chemoradiotherapy significantly improved DFS in patients with node-positive disease and with intestinal-type GC. There was a similar trend for DFS and OS by stage of disease. Conclusion In D2-resected GC, both adjuvant chemotherapy and chemoradiotherapy are tolerated and equally beneficial in preventing relapse. Because results suggest a significant DFS effect of chemoradiotherapy in subsets of patients, the ARTIST 2 trial evaluating adjuvant chemotherapy and chemoradiotherapy in patients with node-positive, D2-resected GC is under way.


1997 ◽  
Vol 88 (4) ◽  
pp. 363-368 ◽  
Author(s):  
Chie Furihata ◽  
Masae Tatematsu ◽  
Masae Saito ◽  
Shizuka Ishida ◽  
Hayao Nakanishi ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e15095-e15095
Author(s):  
Vladimir Sez Trifanov ◽  
Tanzila Beksultanovna Kazieva ◽  
Konstantin Vladimirovich Dvadnenko ◽  
Martin Zamirovich Tatimov ◽  
Alexander V. Snezhko ◽  
...  

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 95-95
Author(s):  
Haa-na Song ◽  
Jinhyun Cho ◽  
Ki Sun Jung ◽  
Su Jin Lee ◽  
Seung Tae Kim ◽  
...  

95 Background: To evaluate the risk of recurrence in patients with pathologically staged Ib, according to the American Joint Committee on Cancer (AJCC) 2002 staging system, gastric cancer (GC) in the phase III adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. Methods: Among 458 GC patients enrolled in ARTIST, 99 had stage Ib (T2N0 or T1N1) disease. Patients were randomly assigned to receive adjuvant chemoradiotherapy with capecitabine plus cisplatin (XP, n = 50)) or chemoradiotherapy (XPRT, n = 49). Kaplan-Meier method was used to calculate disease-free survival (DFS). Cox proportional hazard models were employed to determine associations between the addition of radiotherapy to XP and DFS after adjustment for patient and disease characteristics. Additionally, analyses were performed according to the AJCC 2010 staging system. Results: With 7 years of follow-up, there were 18 recurrences. The 5-year DFS rates were 88% and 84% in XP and XPRT patients, respectively (P = 0.537). When we reviewed the pathologic stages of the patients according to the AJCC 2010 system, stage migration from Ib to II occurred in 71% of the patients: 98% of the T2N0 patients were reclassified as T3N0, and 42% of the T1N1 patients were reclassified as T1N2. The patients classified as stage Ib according to the AJCC 2002 system and reclassified as stage II exhibited worse, although statistically insignificant, prognosis than the patients who remained in stage Ib (5-year DFS 83% vs. 93%, P = 0.183, HR 1.178, 95% CI 0.420-3.311, P = 0.158). When we compared 5-year DFS in 70 stage II (AJCC 2010 system) patients, the addition of radiotherapy to XP chemotherapy resulted, although again statistically insignificant (P = 0.234), in worse outcome in XPRT arm (77%) than in XPRT arm (88%). Conclusions: This subgroup analysis confirms the clinical relevance of the AJCC 2010 staging system in GC. The role of adjuvant chemotherapy in stage II GC warrants further investigation.


2015 ◽  
Vol 26 ◽  
pp. iv29 ◽  
Author(s):  
K.H. Yoo ◽  
S.H. Park ◽  
S.J. Lee ◽  
S.T. Kim ◽  
J. Lee ◽  
...  

2020 ◽  
Vol 10 (5) ◽  
Author(s):  
Minh Đức Hoàng ◽  

Abstract Introduction: To diagnose and classify for non-epithelial tumors of the stomach was difficult for physicians because of its non-specific symptoms and intensive diagnostic methods. Materials and Methods: Descriptive cross-sectional retrospective study, monitoring cases of non-epithelial tumors of the stomach surgery at Viet Duc University Hospital from 4/2014 to 5/2019. Results: In 144 cases of non-epithelial tumors of the stomach, there were 122 cases of GIST (stromal tumors had most rate 62,5%), 22 cases of gastric lymphomas, the average age was 56.9, male/female ratio was 1/1, however GIST and lymphomas being seen more in man than woman, in other side, leiomyomas and Schwann tumors being seen more in woman than a man. Diagnosis of non-epithelial gastric tumors mostly by endoscopy (87.9% tumors discovered), by ultrasound through endoscopy (100% tumors found, in that, 2 cases of lymphomas seen with the thick gastric wall), by belly ultrasound (79/113 cases, 59.4%), by CT-Scanner (100% tumors found). Diagnosis of classifying tumor by pathology: Lymphomas (100%), gastrointestinal stromal tumors (GIST) only classified by immunohistochemistry (IHC): stromal tumors (positive marker DOG1 100%, CD17 96,9%, CD34 92,9%), leiomyomas (positive marker Desmin 100%, SMA 90%), Schwann tumors (positive marker S100 100%). Conclusions: Common non-epithelial stomach tumors at Viet Duc University Hospital are stromal tumors, lymphoma, Schwann’s tumors, smooth muscle tumors also fat tumors. Diagnosis is confirmed based on disease anatomy and immunohistochemistry results with markers DOG1, CD17, CD34, Desmin, SMA, S100. Keywords: Non-epithelial tumors of the stomach, diagnose, classify, gastrointestinal stromal tumors (GIST), lymphomas, leiomyomas, Schwann tumors. Tóm tắt Đặt vấn đề: Chẩn đoán và phân loại các u dạ dày không biểu mô là một vấn đề khó đối với thầy thuốc bởi các triệu chứng thường không đặc hiệu và phương pháp chẩn đoán chuyên sâu. Phương pháp nghiên cứu: Nghiên cứu mô tả cắt ngang hồi cứu các trường hợp phẫu thuật u dạ dày không biểu mô tại Bệnh viện Hữu nghị Việt Đức từ tháng Kết quả: Có 144 người bệnh u dạ dày không biểu mô được phẫu thuật tại Bệnh viện Hữu nghị Việt Đức, trong đó có 122 người bệnh u trung mô (trong đó u mô đệm chiếm nhiều nhất 62,5%), 22 trường hợp u lympho, nhóm nghiên cứu có tuổi trung bình là 56,9, tỷ lệ nam/nữ là 1/1. Tuy nhiên u mô đệm và u lympho gặp ở nam nhiều hơn ở nữ và ngược lại, u cơ trơn và u Schwann gặp ở nữ nhiều hơn ở nam. Chẩn đoán u dạ dày không biểu mô chủ yếu bằng nội soi (87,9% phát hiện u trên nội soi), siêu âm nội soi (100% trường hợp phát hiện u, trong đó 2 trường hợp u lympho thấy dày thành dạ dày), siêu âm ổ bụng (79/133 trường hợp, 59,4%), chụp cắt lớp vi tính (100% phát hiện ra u). Chẩn đoán xác định loại u dựa vào kết quả giải phẫu bệnh: U lympho (100%), các loại u trung mô khác phải dựa vào hoá mô miễn dịch: u mô đệm (dương tính với dấu ấn DOG1 là 100%, CD17 là 96,9%, CD34 là 92,9%), u cơ trơn (dương tính với dấu ấn Desmin 100%, SMA là 90%), u Schwann (dương tính với S100 là 100%). Kết luận: U dạ dày không biểu mô thường gặp tại Bệnh viện Hữu nghị Việt Đức là u mô đệm, u lympho, u Schwann, u cơ trơn và u mỡ. Chẩn đoán xác định dựa vào giải phẫu bệnh và kết quả hoá mô miễn dịch với các dấu ấn DOG1, CD17, CD34, Desmin, SMA, S100.


Sign in / Sign up

Export Citation Format

Share Document